WASHINGTON - The third meeting of the National Task Force on AIDS Drug Development continued its exploration of surrogate markers last week without reaching any conclusions, although the FDA proposed to establish two panels to continue work on the issue.

The agency proposed to form a subcommittee of existing advisory committees devoted to surrogate markers and to form a separate working group to validate surrogate markers in clinical trials.